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Abstract  
 
Surgery is a mainstay of treatment for solid tumours. Despite surgical resection with 
curative intent and advances in (neo)adjuvant therapies, metastatic disease remains 
common and carries high mortality. The biological perturbation that accompanies the 
surgical stress response and the pharmacological effects of anaesthetic drugs may 
paradoxically promote progression of metastatic disease. When cancer cells persist 
after surgery either locally or at undiagnosed distant sites, neuroendocrine, immune, 
and metabolic pathways, which are activated in response to surgery and anaesthesia, 
may promote their survival and proliferation. The consequence is that minimal 
residual disease may escape equilibrium and progress to metastatic disease. Here, we 
discuss leading proposals for refinement of perioperative care that address these 
challenges. We outline the rationale and early evidence for the adaptation of 
anaesthetic techniques and strategic use of anti-adrenergic, anti-inflammatory, and 
anti-thrombotic therapies. Many of these strategies are now under evaluation in major 
cancer surgery trials and hold promise as affordable, readily available measures to 
improve post-operative recurrence-free survival. 
  
 3 
Introduction 
 
Surgery is the foremost treatment strategy for the majority of solid tumours. However, 
even where complete loco-regional control is thought to have been achieved, post-
operative recurrence is common and carries high mortality
1
. The stress response to 
surgery activates physiological responses that have evolved to promote wound 
healing after injury. These include neural, inflammatory, and pro-angiogenic 
signalling pathways, which also promote cancer growth and metastasis. 
Unsurprisingly, accumulating evidence suggests that perioperative events promote 
recurrence by enhancing growth of pre-existing micrometastatic disease or by 
facilitating a residual fraction of tumour cells to develop loco-regional recurrence or 
seed new metastatic disease
2-4
.   
 
Over a century ago, Paget proposed a ‘Seed and Soil’ framework that described 
metastasis in terms of cancer cell dissemination and colonization in ‘fertile soil’5. 
Such an analogy is highly relevant to the perioperative period, when both cancer cell 
dissemination and perturbations in tissue environments occur. Handling of the tumour 
during surgery can release cancer cells into circulation (the seed)
6-8
. Meanwhile, 
vulnerability to colonization arises from the modulation of immune function and the 
activation of neural-inflammatory signalling, which may prime local and distant tissue 
beds to form a privileged microenvironment (the pre-metastatic niche, or soil)
9,10
. 
This period of vulnerability may extend in excess of a week after surgery and help the 
‘seed’ to ‘germinate and fertilize’ and thereby establish viable minimal residual 
disease
11,12
. As a consequence, local cancer recurrence or metastasis development 
following surgery has been documented in numerous tumour types including 
breast
13,14
, ovarian
15
, lung
16
, and colorectal cancers
17
.  
 
Clinical findings suggest that the magnitude of surgery and protracted inflammation 
caused by post-operative complications may further increase the risk of disease 
recurrence. For example, compared with a simple mastectomy, an additional invasive 
reconstructive procedure alters cancer recurrence dynamics
18,19
. Additionally, post-
operative complications such as wound infection
2,3
 or anastomotic leak
4,20
 have been 
associated with poor cancer-related outcomes. Alarmingly, recent clinical studies 
raise the possibility that the choice of anaesthetic agent may also impact long-term 
survival in patients with cancer
21,22
. This emphasizes the patient vulnerability to 
recurrence that arises from exposure to perioperative events. 
 
The potential magnitude of impact of this perioperative vulnerability is underscored 
by the fact that more than 60% of the over 15 million patients diagnosed with cancer 
each year will require surgical resection
23
, and that more than 80% of cancer patients 
will be exposed to anaesthesia for either curative, diagnostic or palliative 
procedures
24
. As such, any opportunity to abrogate cancer risk arising during the 
vulnerable perioperative period may lead to substantial benefit for patients globally. 
Here, we review the biological processes that underpin this vulnerability to cancer 
recurrence, as well as the accumulating pre-clinical and clinical evidence that 
anaesthetic and adjunctive strategies may modulate the risk of cancer recurrence 
following surgery. 
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Pathophysiological response to surgery 
 
Post-operative recurrence frequently takes the form of metastatic disease
13,14
. The 
traditional paradigm sees metastasis as a late event in the stepwise, Darwinian-like 
evolution of cancers, occurring only when cells acquire a complementary set of 
somatic genetic changes that allow escape from the primary tumour, entry into the 
lymphatic or vascular network, circulatory survival, and an ability to establish growth 
at ectopic sites
25. The “parallel progression” model challenges this perspective, 
unifying a series of clinical and experimental observations that collectively suggest 
that dissemination and distant colonization occur early in the development of a 
cancer
26
. Early support for this came from genetic analyses of patients with breast 
cancer, where disseminated tumour cells isolated from bone marrow displayed fewer 
genetic aberrations than their matched primary tumour counterparts
27
. More recently, 
the phenomenon has been captured and mechanistically characterized in animal 
models of pancreatic cancer
28
 and breast cancer
29
, in which epithelial-mesenchymal 
transition programmes promoted the dissemination and distant colonization of early 
cancer cells even before primary tumours had become detectible. In the perioperative 
context, these findings suggest that cells liberated during surgery, even when 
originating from very early-stage tumours, may be competent to disseminate and form 
metastases.  
 
Moreover, it is increasingly evident that the fate of disseminated tumour cells may be 
determined by the conditions encountered during transit and the early stages of 
colonization. Events during intravascular passage, such as interactions with activated 
platelets, neutrophils, and endothelial cells, as well as transient exposure to pro-
metastatic, pro-angiogenic signals that accompany the surgical inflammatory response 
may improve metastatic efficiency
25
. Given that the pathophysiological response to 
surgery bears many similarities with conditions that are favourable for cancer 
progression, it follows that events in the perioperative period could influence the 
viability and subsequent expansion of distant colonies arising either from tumour cells 
disseminated during surgery, or from undiagnosed micrometastatic sites that were 
held in equilibrium prior to surgery. Here, we review the events of cancer cell 
dissemination and colonization that are impressionable to perioperative factors 
(summarized in Table 1). 
Intra-operative tumour cell dissemination 
Tumour cell dissemination occurs via haematogenous, lymphatic, and transcoelomic 
routes. Circulating tumour cells (CTCs) are detectable in the majority of patients with 
solid tumours
30
, and elevated CTC levels have been linked to poor prognosis in 
various tumour types
31,32
. CTC numbers have been demonstrated to rise following 
surgery for breast
6
, lung
7
, and colorectal
8
 cancers. While there is inconclusive 
evidence that CTC elevation correlates with poor outcomes in all tumour groups
33
, it 
understandably raises concern that CTC release during surgery contributes to 
metastatic colonization.  
 
Dissemination of tumour cells through lymphatic vasculature occurs in response to 
mechanical (surgical) disruption and has been captured using real-time fluorescence 
imaging
34
. A four-fold increase in tumour cells was detected in sentinel lymph nodes 
following breast cancer surgery
35
. Tumours have an elevated interstitial pressure that 
favours lymph flow to adjacent lymph nodes and this is enhanced by the normal 
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mechanisms of lymphatic clearance of pericellular debris that follow wounding
36,37
. 
The inflammatory-mediated endothelial disruption resulting from surgical incision 
elevates both the hydrostatic and oncotic pressures in the interstitium, thereby leading 
to interstitial oedema, lymphatic transit of residual tumour cells and subsequent 
dissemination
36,37
. This physiological response to wounding, with up-regulation of 
lymphangiogenic factors including vascular endothelial growth factor (VEGF), 
prostaglandins, and platelet derived growth factor (PDGF), may further enhance 
tumour cell dissemination and viability of residual disease
38,39
.  
 
Transcoelomic dissemination of colorectal, pancreatic or ovarian cancers during intra-
abdominal surgery is a well-described phenomenon
17
 and contributes to peritoneal 
carcinomatosis
40
. This vulnerability for subsequent recurrence is highlighted by the 
finding that up to one quarter of patients had detectible residual intra-abdominal 
cancer cells following colorectal surgery
41
. Intra-abdominal spread of tumours at the 
time of surgery may be further accelerated by the process of dehumidification, which 
occurs during gas (carbon dioxide) insufflation to facilitate laparoscopic surgery
40
. 
Dissemination of tumour cells may also be induced directly by the surgical procedure, 
for example the use of laparoscopic ports may result in port site recurrence. This 
phenomenon has been reported following surgery for gastrointestinal
42
, 
gynaecological
43
, urological
44
, and thoracic
45
 malignancies, and alarmingly was 
recently reported to be over 10% following gall-bladder resection where incidental 
malignancy was diagnosed
46
.  
Inflammation and wound healing after surgery 
Wound healing following surgery and tumour growth share common inflammatory 
processes, and a transcriptional ‘wound response signature’ resembles that expressed 
by malignant cells
47
. However, where wound repair and cancer growth fundamentally 
diverge is in the employment of self-limiting mechanisms; Dvorak labelled tumours 
as “wounds that do not heal”48.  
Inflammatory changes that occur at the surgical site following cancer resection 
include recruitment of numerous cell types and release of humoral factors. Recruited 
macrophages and neutrophils, which secrete factors such as VEGF and matrix 
metalloproteinases (MMP), are known to promote cancer growth and dissemination
49
. 
Similarly, tissue trauma recruits fibroblasts and mesenchymal stem cells to sites of 
endothelial activation; these cells release soluble growth factors to form ideal growth 
conditions for residual cancer cells
50
. Surgery elevates inflammatory mediators such 
as prostaglandin E2 (PGE2)
51
, which promotes an immunosuppressive environment 
through expansion of cancer-promoting regulatory T cells (Treg), reduction of CD8+ T 
cells, and a shift from anti-tumour Th1 to Th2 cytokines
52,53
. Surgical wounding also 
disrupts local vasculature, causing subsequent wound hypoperfusion (ischaemia) and 
hypoxia
54
. Hypoxia stimulates expression of hypoxia-inducible factor (HIF)
55
, which 
supports cancer metabolism to drive tumour growth in a broad range of cancers
56
.  
Consistent with Paget’s enduring ‘seed and soil’ model, an inflamed surgical wound 
temporarily may be an attractive site for colonization by CTCs. Inflammation denudes 
the microcirculatory endothelium, potentially creating a pre-metastatic niche. 
Notably, in animal models injected cancer cells preferentially metastasize to regions 
of wounding (traumatic incision) or surgically related inflammation
40,57,58
 and 
experimental models have shown that wound dehiscence is elevated in mice with 
disseminated tumours
59
. Tumour cell dissemination to sites of inflammation may 
 6 
explain the observed clinical phenomena of cancer recurrence at the site of a colonic 
anastomosis or abdominal port insertion
4,20,44,46
.  
Together, the processes of a local inflammatory wound response and systemic 
inflammation may activate dormant micrometastasis or propagate residual cancer 
cells to increase the risk of cancer recurrence. In vivo studies found that wound 
derived fluid, which is rich in PDGF, VEGF, and epidermal growth factor, stimulates 
lymphangiogenesis and angiogenesis leading to rapid neovascularization of dormant 
tumours (micrometastasis)
38,39,60,61
. Leukocytes that migrate into a surgical wound 
have been shown to induce proliferation of dormant tumour cells
62
. Increased 
inflammatory response following surgery correlates with increased metastasis 
development in animal models
63
, and patients with a high neutrophil to lymphocyte 
ratio are more prone to cancer recurrence
64
. The contribution of inflammatory wound 
repair processes to tumourigenesis may explain why surgical complications including 
surgical wound infections (Odds Ratio [OR] 2.87, 95% Confidence Interval [CI]: 
1.97-4.18)
2
, post-operative anastomotic leak (OR 1.61, 95% CI: 1.25-2.09)
4
, and 
increased perioperative systemic inflammatory response are associated with elevated 
cancer recurrence
65
.  
Activation of neural signalling  
The surgical stress response is characterized by activation of neural signalling, which 
is induced by surgical tissue trauma as well as the pathophysiological stress effects of 
patient anxiety, hypothermia, metabolic derangements, and fasting (Figure 1)
66
. 
Increased neural signalling elevates circulating catecholamine levels that act through 
β-adrenoceptors to induce pro-metastatic effects on both tumour cells and the tumour 
microenvironment to support cancer recurrence
67-70
. Consistent with this, in vivo 
cancer models have demonstrated that more invasive surgery and high levels of 
neural-inflammatory signalling are linked with increased tumour progression
15,63
.  
 
In vivo studies show that neural signalling through β-adrenoceptors enhances cancer 
progression in models of breast
67,68
, pancreas
69
, colon
71
, neuroblastoma
72
, ovarian
70
, 
and prostate cancers
73,74
. Studies have shown that β-adrenoceptors are up-regulated on 
tumour cells
75
, and activation increases invasion and dissemination in vivo
76
. The 
signalling pathways that are activated in tumour cells by β-adrenoceptor stimulation 
include a calcium-cAMP signalling loop that enhances transcription of pro-metastatic 
factors including HIF, VEGF, and MMP
67,69,77
. Activation of these signalling 
pathways results in structural changes in tumour cells that increase formation of 
invadopodia
78
 and reduce cell deformability resulting in contractile, invasive cells
77,79
.  
 
Neural signalling also remodels the architecture of the tumour microenvironment to 
accelerate cancer progression. β-adrenoceptor signalling remodels tumour-associated 
lymphatic and blood vasculature through inflammation-dependent mechanisms
67,68,70
. 
The sympathetic nervous system also regulates lymphatic flow through innervation of 
lymphangions – structural contractile elements that surround lymphatic vessels and 
regulate pumping
34,80,81
. A recent study found that neural signalling accelerates flow 
through lymphatic vessels that drain the primary tumour, thereby increasing 
dissemination of tumour cells in vivo
68
. These findings raise the possibility that 
modulation of lymphatic flow during surgery may enhance tumour cell dissemination. 
This may have significant implications for recurrence incidence, as activation of 
neural pathways is elevated in more invasive surgery
82
, and an exaggerated 
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perioperative neural-inflammatory response has been linked to poor cancer-free 
survival
65
. 
 
Neural signalling may also enhance recurrence by creating a metastatic 
microenvironment that promotes growth of disseminated tumour cells. Stimulation of 
β2-adrenoceptors on osteoblasts up-regulates the Receptor Activator of Nuclear Factor 
Kappa-B Ligand (RANKL), which increases osteoclast activity and induces a 
microenvironment in the bone that supports expansion of metastasis
83,84
. Together 
these observations suggest that elevated neural signalling in the perioperative period 
is an important factor that may contribute to the growth of residual cancer cells (seed) 
and may assist the establishment of distal sites of cancer deposition (soil). 
Surviving a hostile circulatory system 
For tumour cells to survive in circulation they must withstand shear forces, a lack of 
supporting extracellular matrix, as well as evade detection by circulating immune 
defences. For these reasons, few CTCs are thought to accomplish colonization of 
distal sites
85
. Nevertheless, injected cancer cells preferentially colonize areas of 
surgical inflammation
58
 and in patients, CTCs home to wounds, infection sites or 
areas of tissue trauma
2-4,57,86
. This raises the possibility that colonization is enhanced, 
or at least is more efficient during and after surgery (Figure 2). Understanding the 
mechanisms that support CTC survival in the perioperative setting may lead to 
interventions that reduce the odds of successful colonization. 
 
Following surgical injury, activation of platelets and tissue factor initiates coagulation 
to achieve haemostasis. However this pro-coagulant and pro-thrombotic state may 
confer vulnerability to malignant processes. Almost a third of patients have 
thrombocytosis at the time of ovarian carcinoma diagnosis
87
, and a recent systematic 
review found perioperative platelet elevation associates with deleterious cancer 
outcomes
88
. Micro-clot formation and ‘platelet cloaking’ of liberated CTCs affords 
protection from vascular shear stress
89
, natural killer (NK) cell-mediated detection, 
and facilitates microvascular arrest by promoting CTC attachment to the 
endothelium
90
. By avoiding detection and elimination by marginated leukocytes in the 
‘slow circulation points’ of the pulmonary and hepatic capillaries, CTCs are able to 
survive extravasation and establish metastases
91
. Inhibition of these platelet and 
clotting pathways (tissue factor, thrombin, von Willebrand factor) greatly reduces 
metastasis in mouse models of cancer
92-94
. Activation of platelets and neutrophils 
triggers the formation of ‘neutrophil extracellular traps’ (NETs) within sinusoids of 
the liver and lungs. NETs are created when activated neutrophils externalize their 
nuclear DNA to form web-like structures. While these inflammatory adaptations may 
be advantageous to trap parasites and bacteria, NETs have also been shown to trap 
CTCs during cancer surgery
95,96
. 
 
Following tissue injury, CTC survival and colonization is also influenced by 
production of the enzymes heparanase and hyaluronidase. Both enzymes are produced 
by cancer cells and are vital to the process of endothelial glycocalyx breakdown that 
facilitates the adhesion (colonization) and invasion of CTCs at metastatic sites
97,98
. 
The efficiency of colonization may be further improved by inflammatory mediators 
that aid the destruction of the endothelial glycocalyx, with endothelial denudation 
forming a pre-metastatic niche
9
. This comprizes clusters of bone-marrow derived cells 
that populate and pre-condition an environment for subsequent CTC infiltration and 
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colony expansion
99
. Pre-metastatic niche formation may also be enhanced by hypoxic 
conditions created at the site of surgical resection and by the actions of platelets that 
release chemokines that are attractive to bone-marrow derived cells
10
. Therefore, 
perioperative strategies that prevent conditions that favour the formation of a pre-
metastatic niche (such as thromboses, NETs, and hypoxia) may reduce recurrence 
after surgery.  
Immune escape 
Primary cancers and metastases employ a range of strategies to evade immune 
detection, many of which are enhanced in the inflammatory aftermath of surgery. The 
inflammation, acidosis, and hypoxia that accompany local tissue injury influence 
infiltrating immune cells, for example promoting M2 macrophage activity and 
suppressing anti-tumour immune responses
100
. Furthermore, under the influence of 
inflammatory mediators such as PGE2, tumour cells shed surface ligands to prevent 
recognition by immune cells, including NK cells
101
. Such effects can hence lead to a 
temporary pro-cancer milieu in the surgical wound or at sites of micrometastasis that 
may increase the risk of recurrence
4,20
.  
 
Following surgery, a protracted period of immunosuppression ensues: a 
counterbalancing phenomenon that has evolved to contain the intensity of the acute 
inflammation, but may also contribute to the perioperative vulnerability to cancer 
recurrence. Activation of the hypothalamic-pituitary-adrenal axis by physical and 
psychological perioperative stressors results in release of glucocorticoids, 
catecholamines, and cytokines that promote surgically-induced 
immunosuppression
66,102
. The systemic immune consequences of these effects include 
diminished number and cytolytic capacity of NK and CD8+ T cells, and increased 
pro-tumour Treg and Th2 cell levels
11,12
. These changes have been shown to increase 
post-operative metastatic disease in animal models of cancer
103-105
, and are associated 
with increased risk of cancer recurrence and mortality in a variety of tumour types in 
patients
106
. Hence, minimizing the surgical stress response and limiting the 
subsequent immunosuppression to that required for healing the surgical wound might 
be a strategy to reduce the vulnerability to cancer recurrence following surgery. 
 
 
Reducing vulnerability to cancer recurrence 
 
The capacity of surgery-induced neural-inflammatory signalling to enhance growth of 
residual or disseminated tumour cells suggests that it may be possible to improve 
cancer survival by emphasizing therapeutic strategies that reduce the surgical stress 
response. This is timely, as a recent international oncoanaesthesia consensus panel 
prioritized systematic investigation of perioperative factors that potentially influence 
cancer recurrence
107
. It will be important to define the magnitude of effect of 
perioperative factors on long-term cancer recurrence through randomized, placebo-
controlled prospective trials. However, these will take a decade or more to recruit, 
monitor outcomes, and report findings. Meanwhile, there is considerable evidence 
available from pre-clinical and clinical studies that agents with anti-adrenergic, anti-
inflammatory, or anti-thrombotic properties, as well as specific anaesthesia 
techniques, may have anti-cancer benefits (Table 2). As these drugs are already 
approved for use in the perioperative period, these findings raise the possibility that 
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their strategic use during cancer resection surgery could reduce opportunity for later 
recurrence and be readily implemented with minimal cost.  
Blockade of sympathetic nervous system signalling  
Expanding evidence from pre-clinical research
68
 and retrospective studies
108,109
 
suggest that blockade of peripheral sympathetic nervous system (SNS) signalling may 
be an effective adjunctive anti-oncogenic strategy. Perioperative SNS blockade may 
be achieved pharmacologically by β-adrenoceptor antagonism or by the delivery of 
neuraxial anaesthesia. Several prospective trials are currently assessing the role of 
perioperative beta-blocker treatment on improved cancer outcomes after surgery in 
patients with breast (NCT00502684, NCT01847001, NCT02596867), melanoma 
(NCT01988831), and colorectal (NCT00888797) cancer. Further studies are 
investigating the impact of perioperative neuraxial anaesthesia on cancer-specific 
outcomes in colorectal (NCT00684229, NCT0131861, NCT02314871), melanoma 
(NCT01588847), breast (NCT00418457), and lung (NCT02801409, NCT02840227) 
cancer. 
 
For patients with cancer, co-incidental beta-blocker use at the time of diagnosis is 
associated with oncological benefit across a broad range of tumours as reported in 
both retrospective studies
110
 and prospective trials
111,112
. In particular, the non-
selective beta-blocker propranolol is associated with improved survival in breast 
cancer (Hazard Ratio [HR] 0.50, 95% CI: 0.32-0.80)
113
, specifically in early stage 
disease (HR 0.19, 95% CI: 0.06-0.60)
108
. Propranolol inhibits a variety of β-
adrenoceptor-mediated cancer processes including tumour cell invasion
78
, 
angiogenesis
70
, lymphangiogenesis
68
, and epithelial-mesenchymal transition
114
. 
Propranolol administration is thus a strategy that could be used perioperatively to 
inhibit the brief period of surgery-induced neural activation and its adverse effects on 
cancer processes. This has been successfully demonstrated in vivo where brief, 
clinically-relevant dosing of propranolol (for example, as would occur prior to 
surgery) reduced tumour cell proliferation, lymph drainage, and metastatic 
colonization by tumour cells
68,104
.  
 
Two recently completed randomized double-blind clinical trials have translated these 
pre-clinical findings to the cancer surgical setting. In one surgical trial, women were 
prescribed either the non-selective β-adrenoceptor antagonist propranolol (40 mg 
daily) combined with the anti-inflammatory etodolac (800 mg daily), or placebo, for 
five days prior to breast cancer surgery
115
. The investigators found that drug treatment 
(compared with placebo) buffered the surgical stress response, as indicated by 
reduced serum inflammatory markers at the time of surgery (interleukin-6, C-reactive 
protein). Treatment also buffered an increase in serum inflammatory markers from 
pre-treatment until the day of surgery, suggesting pre-operative anxiety may prime 
patients’ stress response prior to surgical injury. Notably, drug treatment also reduced 
tumour gene expression signatures that were characteristic of pro-metastatic 
transcription factors, myeloid recruitment, and epithelial-mesenchymal transition. 
These findings demonstrate that brief blockade of perioperative neural-inflammatory 
signalling downgrades the malignant potential of tumour cells at the time of surgery. 
It will be important to define the relative contributions of beta-blockade and NSAIDs 
to these effects. A separate surgical trial examined the effect of propranolol (60 mg 
daily) on post-operative immune cell changes
12
. Beta-blocker treatment that was 
commenced on the day of mastectomy surgery mitigated post-operative elevation of 
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Treg cells and suppression of tumour antigen-specific CD4 T cell response.  
 
These findings raise the possibility that perioperative modulation of neural-
inflammatory signalling may offset surgery-related immunosuppression and 
potentially reduce the malignant potential of residual cancer cells. Large trials have 
shown that clinicians must be cautious with prescription of cardio-selective beta-
blockers in patients at risk of cardiac events
116
, especially when administered in a 
high dose in the immediate preoperative period. However, propranolol may be more 
suitable for use in the perioperative oncoanaesthesia context as it is not cardio-
selective, is used as a pre-operative anxiolytic
117
, and has now demonstrated safety in 
two prospective cancer trials
12,115
.  
 
An alternate means of achieving sympathetic blockade during cancer surgery is 
through neuraxial anaesthesia that reduces circulating catecholamines
82
, 
inflammation, and immunosuppression
118-120
. Furthermore, a recent study reports that 
perioperative lymph flow is inhibited by neuraxial anaesthesia
81
, a phenomenon also 
documented in animals
121. This raises the intriguing possibility that a potential ‘anti-
cancer’ benefit from neuraxial anaesthesia may result from a reduction in 
dissemination of residual cancer cells from a surgical wound. As a commonly used 
perioperative analgesic technique, neuraxial anaesthesia allows clinicians to 
implement opioid-sparing perioperative care
109,122
. This approach is thought to be 
advantageous during cancer surgery due to in vivo evidence of tumour promoting 
effects by opioids
123
. What is clear is that avoidance of perioperative opioids when 
endeavouring an opioid-free anaesthetic should not be undertaken if it risks poorly 
managed perioperative pain and thus sympathetic activation
124
. Overall, recent meta-
analyses show that perioperative neuraxial anaesthesia is associated with a survival 
benefit (HR 0.85, 95% CI: 0.74-0.98)
125
, HR 0.84, 95% CI: 0.75-0.94
126
). Neuraxial 
anaesthesia is already in routine use during cancer surgery when indicated. Whether it 
or perioperative beta-blockade provide cancer-specific benefit for patients will require 
evidence from the randomized trials listed above that target long-term recurrence 
outcomes.  
Anti-inflammatory therapy 
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the 
perioperative setting as analgesics and may also have additional anti-cancer benefit. 
NSAIDs are non-selective (aspirin, diclofenac, naproxen, ibuprofen, ketorolac) or 
selective for either the constitutive cyclo-oxygenase (COX)-1 isoform (ketoprofen) or 
inducible COX-2 isoform (celecoxib, parecoxib, etodolac, rofecoxib). Several clinical 
trials are currently investigating the impact of routine perioperative NSAIDs on 
reducing cancer recurrence: two are currently closed for follow-up (NCT01806259, 
NCT02429427), and two are actively recruiting in breast (NCT00502684) and colon 
(NCT00888797) cancer surgery.  
 
NSAIDs inhibit tumour-associated inflammation, which reduces angiogenesis and 
lymphangiogenesis to block metastasis in animal models of cancer
68,127
. This suggests 
that perioperative NSAID use may limit surgically-induced inflammatory states. 
Consistent with this, use of NSAIDs during surgery reduced inflammation and NK 
cell suppression, and prevented metastasis in mouse models of cancer
103,105
.  
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Clinical studies also suggest that NSAIDs exert localized and systemic anti-
inflammatory and immune effects. Recent surgical trials have shown perioperative 
administered COX-2 inhibitors reduce systemic and wound prostaglandin levels
128,129
, 
suppress catecholamine and cytokine levels
128,130
, and buffer both Treg elevation
131
 
and NK cell decline
132
. NSAIDs have an established chemoprevention role in a 
variety of tumour types
133,134
, and their pre-operative use reduces intra-tumoural 
VEGF expression, lymphangiogenesis, and Treg infiltration
135,136
. While these clinical 
studies point to an indirect anti-cancer benefit, several studies have also reported an 
association between use of perioperative NSAIDs and improved cancer outcomes for 
patients
137-139
. The largest of these studies investigated 15,574 patients receiving liver 
resection for hepatocellular carcinoma and found an association between 
perioperative administration of NSAIDs and reduced cancer recurrence (HR 0.81, 
95% CI: 0.73-0.90)
139
. COX-2 inhibitors have been recommended over other NSAIDs 
for post-operative analgesia during cancer surgery
122
. 
Anaesthetic drugs 
 As early as the 1980s, experimental research demonstrated that anaesthetic drugs 
influence cancer cell proliferation and metastasis
140
. Recent evidence suggests that the 
two most common anaesthesia agents – intravenous propofol and inhalational volatile 
– have distinct influences on inflammation, immune cell phenotypes and cancer 
processes. Given that nearly 80% of the 15 million new patients diagnosed annually 
with cancer will require anaesthetic agent exposure, improving our understanding of 
the divergent impact of these agents on cancer biology will guide appropriate 
anaesthetic choice for cancer surgery
24 . 
Inhalational anaesthetics 
Inhalational halogenated hydrocarbon anaesthetics including isoflurane and 
sevoflurane are well known to afford a degree of cytoprotection to organs such as the 
heart, brain, and kidneys, and reduce both infarct size and functional impairment in 
models of ischemia-reperfusion injury
141
. However, these properties may make them 
deleterious in the cancer setting. Their cytoprotective effects have been linked to HIF-
1α up-regulation, and could confer a survival benefit on residual cancer cells142. This 
hypothesis is supported by recent in vitro studies, where exposure to even brief 
periods of isoflurane led cancer cells to up-regulate HIF-1α, HIF-2α, and transforming 
growth factor-β, and increase transcription of pro-metastatic factors (VEGF, 
angiopoietin-1, proteases MMP-2 and MMP-9)
143,144
 which enhanced tumour cell 
proliferation and migration
145-147
. In vivo studies show that isoflurane modulates 
Th1:Th2 ratios
148
, impairs NK cell activity
149
, and enhances the migration of cancer 
cells
150
. Inhalational anaesthetic agents may thus promote immunosuppression and a 
pro-malignant environment that supports growth of residual cancer cells. Taken 
together with the available clinical data, the currently routine practice of using 
inhalational anaesthetics for cancer surgery is being questioned and evaluated against 
potentially safer alternatives. This concern achieved further clinical relevance with the 
recent publication of a retrospective, propensity matched cohort of over 7000 cancer 
patients that found use of volatile anaesthesia was associated with a remarkable 
reduction in long-term overall survival after cancer surgery when compared with 
propofol based anaesthesia (22.8% versus 15.6% mortality five years after surgery; 
HR 1.46, 95% CI: 1.29-1.66), even after controlling for patient comorbid risk and for 
metastatic disease at surgery
21
. This is particularly alarming as volatile anaesthesia is 
used in up to 90% of general anaesthetic procedures
151
. Large, prospective multi-
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centre studies are warranted to address the safety of volatile anaesthesia during cancer 
surgery. 
 
Propofol 
The alternative anaesthesia agent in common use during cancer surgery is intravenous 
propofol. Propofol has an appealing anti-cancer profile, and the last three years have 
seen a rapid expansion in the number of prospective trials evaluating its impact during 
cancer surgery (compared with volatile anaesthetic agents) on immune or cancer-
specific biomarkers (NCT03005860, NCT02739958, NCT01418326) or in phase four 
(mortality) studies (NCT01975064, NCT03034096, NCT02660411, NCT02840227, 
ACTRN12617001065381). 
 
The association between propofol and improved patient survival following cancer 
surgery
21,22
 may be linked to its anti-inflammatory properties. Propofol suppresses 
prostaglandin and inflammatory cytokine production in mouse models of cancer
152-154
. 
In patients, perioperative propofol reduces cytokine production
155
 and prevents 
immunosuppression
156
. In vitro and in vivo experiments have shown that clinically 
relevant concentrations of propofol, or serum from patients who were anaesthetized 
with propofol, inhibit cancer cell migration via inhibition of MMP expression, 
preserve NK cell function, and reduce metastasis
157-160
. Increased NK cell infiltration 
of tumours is also reported in patients administered propofol
149
. These findings 
suggest that propofol may provide anti-inflammatory advantages during cancer 
surgery that could confer long-term benefit on cancer outcome. Consistent with this, a 
recently published retrospective study found that in patients undergoing mastectomy, 
propofol anaesthesia was associated with improved survival compared with volatile 
anaesthesia (HR: 0.55, 95% CI: 0.31-0.97)
161
. While more research is required, 
current evidence raises the possibility that total intravenous anaesthesia with propofol 
may become the preferential anaesthetic agent for cancer surgery. 
Anti–thrombotics 
Anti-thrombotic agents such as aspirin and heparin are used during the perioperative 
period to reduce the risk of myocardial infarction, cerebrovascular thrombosis, and 
venous clot formation. By inhibiting platelet cloaking of CTCs, these agents may 
prevent metastatic colonization
162,163
. Several clinical trials are currently investigating 
the influence of perioperative anti-thrombotics on long-term cancer outcomes 
following breast (NCT02927249) and colon cancer surgery (NCT02301286, 
NCT02467582). 
 
In addition to its anti-inflammatory effects, aspirin exerts an anti-thrombotic effect via 
inhibition of thromboxane A2; this may partially explain why aspirin is the only 
NSAID to reduce the incidence of cancer
164
. It has been proposed that reduced 
metastasis in patients receiving aspirin is attributable to impairment of CTC survival 
by the anti-platelet properties of aspirin
165
. Studies have found that daily aspirin use 
following colorectal surgery is associated with reduced metastasis (OR 0·69, 95% CI: 
0·57-0·83) and improved survival (OR 0.62, 95% CI: 0.58-0.67), with similar 
associations seen in oesophageal, breast, gastric, and biliary cancers
166,167
. 
Furthermore, a recently published prospective observational study of patients with 
rectal cancer found those taking low-dose aspirin concurrently with neoadjuvant 
chemotherapy had a favourable pathological response, lower metastasis risk (HR 
0.30, 95% CI: 0.10-0.86), and improved five year progression-free survival (HR 0.20, 
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95% CI: 0.07-0.60)
138
. Perioperative COX activation with CTC release during 
surgical manipulation, and consequent colonization risk represents a cancer 
promoting vulnerability associated with the perioperative period that appears to be 
partially offset by low dose aspirin. While aspirin should be avoided in high risk 
patients
168
, especially with increased bleeding risk, recent guidelines suggest that 
aspirin may be safely incorporated into perioperative treatment to reduce the risk of 
metastasis and cancer mortality
169
. 
 
Alternative anti-thrombotic agents such as heparin have also been shown to prevent 
cancer progression in in vitro and in vivo studies
170
. Heparin inhibits heparanase to 
reduce primary tumour angiogenesis, increase apoptosis, and reduce tumour 
progression
171,172
. Like aspirin, heparin inhibits platelet-CTC complexes
173
, and 
prevents metastasis in experimental models
172,174
. Notably, the beta-blocker 
propranolol may also inhibit thromboxane to reduce platelet aggregation, which may 
contribute to its anti-metastatic properties
175
. Whether anti-thrombotic agents such as 
aspirin achieve a beneficial anti-cancer effect through inhibition of CTC survival 
requires further study. However, the increasing evidence supporting this strategy 
builds a case for their perioperative use in patients at low risk of bleeding 
complications.  
 
 
Translating research: improving clinical practice  
 
More than nine million cancer patients worldwide require cancer surgery each year. 
These patients will be exposed to the pathophysiological stresses of the perioperative 
period and to various anaesthetic techniques. Accumulating evidence points to these 
factors potentially promoting the survival of residual or disseminated cancer cells to 
initiate cancer recurrence. Understanding how perioperative care should be adapted to 
reduce the risk of local or metastatic recurrence is a leading research priority
24,107
. 
Notably, the paucity of robust evidence has resulted in a lack of consensus on optimal 
perioperative care, and no guidelines exist for the choice of anaesthetic technique 
during cancer surgery.  
 
The existing body of evidence suggests that optimal care during cancer surgery will 
employ an anti-adrenergic, anti-inflammatory, anti-thrombotic strategy underpinned 
by the use of neuraxial anaesthesia and total intravenous anaesthesia, and may 
improve long-term survival. On-going clinical trials will provide greater insight into 
the potential anti-cancer benefit of such strategies. The utility of this anaesthetic 
technique may be especially applicable in certain patient sub-groups including those 
with an existing preoperative inflammatory state, those with high CTC load and those 
at an elevated perioperative risk of infectious or anastomotic complications
2,4,65,88,176
. 
 
While many novel oncological therapies are costed in thousands of dollars per patient, 
the perioperative interventions highlighted in this review can be costed in single 
dollar figures per patient. Large prospective clinical trials are required to definitively 
demonstrate the effect of anaesthetic techniques on long-term outcomes after cancer 
surgery. Should this be confirmed, then significant global economic and social 
improvements in cancer outcomes can be achieved for patients at relatively little 
financial cost but with potentially life-changing benefit that will bring about a 
paradigm shift in surgical cancer care. 
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Glossary 
General anaesthesia agent: A drug used to induce and maintain a state of general 
anaesthesia. Broadly categorized as inhaled (e.g., sevoflurane, isoflurane, desflurane) 
or intravenous (e.g., propofol, thiopentone). 
Iatrogenic: Relating to illness or injury caused by medical examination or treatment. 
Neuraxial anaesthesia: An anaesthetic drug placed near the nerves of the central 
nervous system to achieve blockade of sensory and sympathetic nerves. This is 
commonly achieved by subarachnoid or epidural injection.  
Transcoelomic: A route of tumour metastasis across a body cavity or organ surface 
including the pleural or peritoneal surfaces. 
 
Key points 
 While surgery remains the primary treatment for solid tumours, post-operative 
loco-regional recurrence and metastasis occurs frequently and confers a high 
morbidity and mortality. 
 Deleterious aspects of surgery include initiation of local and systemic 
inflammation, a pro-thrombotic state, exposure to anaesthetic drugs, 
immunosuppression, and neural activation of adrenergic signalling. These 
processes overlap with known cancer promoting pathways.  
 During surgery, cancer cells that escape resection are subject to perioperative 
physiological changes, and may disseminate and colonize distant organs, 
contributing to post-operative cancer recurrence. 
 Perioperative use of anti-adrenergic drugs, anti-inflammatories, intravenous 
anaesthesia agents, and anti-thrombotic agents are linked with improved 
cancer survival. 
 Over 60% of patients with cancer are treated with surgery. Off-setting the 
deleterious impact of surgery using affordable and readily available therapies 
may help to rapidly improve post-operative cancer survival.  
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Tables 
 
Table 1. Perioperative events postulated to influence the fate of residual cancer cells 
and post-operative disease recurrence  
Physiological 
response to surgery 
Perioperative  
triggers 
Hypothesized impact upon tumour cells and 
metastasis 
Sympathetic nervous 
system activation 
 
Surgical tissue trauma  
 
Anxiety  
 
Pain  
 
Hypothermia  
 
Fasting 
Increased tumour cell invasiveness  
 
Increased transcription of pro-metastatic factors  
 
Formation of pre-metastatic niche  
 
Increased lymphatic flow and increased trafficking of 
cancer cells  
Inflammation and 
wound healing 
 
Surgical tissue trauma 
 
Provision of favourable growth conditions is amplified by 
influx of immune cells, fibroblasts, and mesenchymal stem 
cells to the wound   
 
Wound hypoxia promotes tumour malignancy and 
treatment resistance through HIF  
 
Endothelial glycocalyx effacement promotes interstitial 
tissue oedema, lymphatic flow, and cell trafficking  
 
Systemic inflammation promotes formation of a pre-
metastatic niche 
Immunosuppression Surgical tissue trauma  
 
Hypothermia  
 
Blood transfusion  
 
Anaesthetic agents 
Inflammation and hypoxia subjects tumour-associated 
immune cells to metabolic stresses, promoting M2-like 
macrophage activity and suppression of anti-tumour 
immune responses  
 
Stress-induced repression of NK and CD8+ cell cytolytic 
capacity and trafficking diminishes efficacy of immune 
surveillance and killing mechanisms against disseminated 
tumour cells  
 
Shift to Th2 cell phenotype and increased Treg numbers 
supports immunoevasion by tumour cells 
Platelet activation  Surgical tissue trauma 
 
Activated platelets shield CTCs from innate immune 
defence mechanisms  
 
NET formation and platelet-CTC aggregates assist CTC 
arrest in distant organ capillary beds 
HIF, Hypoxia-Inducible Factor; NK, natural killer; Treg, regulatory T cell; CTC, circulating tumour cell; NET, neutrophil 
extracellular trap 
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Table 2. Anaesthetic agents and perioperative adjunctive therapies and their potential 
impact upon cancer cells, metastasis, and cancer outcomes 
 
HIF, hypoxia-inducible factor; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinases; TGF-β, 
transforming growth factor; NK, natural killer; HR, hazard ratio; CI, confidence interval; EMT, epithelial mesenchymal 
transition; Treg, regulatory T cell; NSAID, non-steroidal anti-inflammatory drug; CTC, circulating tumour cell 
 
  
Perioperative 
Intervention 
Primary clinical use Impact on tumour physiology 
and metastasis 
Selected supporting clinical 
evidence 
General 
anaesthetics 
 
● Inhalational  
e.g. isoflurane, sevoflurane, 
desflurane for maintenance of 
anaesthesia 
 
● Intravenous  
e.g. propofol; bolus 
administration for induction 
of anaesthesia and 
continuous infusion for 
maintenance  
● Inhalational agents:  
Up-regulate HIF-1, VEGF, MMP, 
TGF-β  
 
Increase cell migration, invasion 
 
Immunosuppression 
 
● Propofol: 
Anti-inflammatory, anti-oxidant  
 
Inhibits cancer cell migration 
 
Preserves T and NK cell function  
● Single-centre retrospective 
analysis of 7,030 patients 
found a HR 1.46 (95% CI: 1.29-
1.66) for death in patients 
receiving inhalational versus 
propofol based anaesthesia21  
Beta-blockers 
 
● Antagonism of β-adrenergic 
receptors to inhibit response 
to endogenous 
catecholamines  
 
● Treat tachycardia, 
hypertension, anxiety  
 
● Inhibit cancer cell invasion, 
lymphangiogenesis, angiogenesis, 
and recruitment of macrophages 
to the tumour 
 
● Reduce lymphatic flow from 
tumours 
 
● Attenuate deleterious effects of 
catecholamine signalling on anti-
tumour immunity 
Phase II trial of perioperative 
propranolol in breast cancer 
found beta-blockade reduced 
EMT, pro-metastatic 
transcription, and 
immunosuppression (Treg, 
CD4+ T cell)12,115 
 
Neuraxial 
anaesthesia 
 
 
● Used as an alternative to 
general anaesthesia for 
lower-body surgery 
 
● Analgesic & anti-adrenergic 
adjunct to general 
anaesthesia 
● Suppresses glucocorticoids, 
catecholamines, and 
inflammatory mediators 
● Meta-analysis reports an 
association between neuraxial 
anaesthesia and overall 
survival HR 0.85 (95% CI: 
0.74-0.98)125 
 
● Conflicting retrospective 
data 
 
Cyclooxygena
se inhibitors 
 
● Anti-inflammatory action to 
reduce prostaglandin 
production 
 
● Used for multi-modal 
analgesia 
 
 
  
● Inhibit a pro-inflammatory 
tumour microenvironment 
(VEGF, Treg infiltration): reduce 
angiogenesis and 
lymphangiogenesis 
 
● Reduce NK cell suppression and 
metastasis in mouse models  
 
 
 
● Retrospective analysis of 
15,574 patients undergoing 
liver resection reports an 
association between NSAIDs 
and reduced recurrence (HR 
0.81, 95% CI: 0.73-0.90)139 
 
● NSAID use associated with 
improved outcomes for 
colorectal and breast cancer 
surgery137,138 
Anti-
thrombotics  
● Heparin used for veno-
thromboembolism 
prophylaxis 
 
● Perioperative aspirin use is 
balanced between 
cardiovascular advantages 
and risks of perioperative 
haemorrhage 
● Heparin inhibits heparanase-
mediated CTC-platelet formation, 
attachment to endothelial 
glycocalyx, and metastasis  
 
● Additional to its anti-
prostaglandin effects, aspirin 
possibly impairs platelet-
mediated CTC survival  
● Perioperative aspirin 
associated with improved 
outcome in breast, 
oesophageal, colorectal, 
gastric, and biliary cancers 
166,167  
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Figure Legends 
 
Figure 1 | The impact of surgery and perioperative stress on the processes of cancer recurrence  
Local tissue injury initiates inflammation and oedema at the wound site, though these effects may 
also facilitate growth of residual tumour cells as well as tumour cell dissemination and distal 
colonization. Systemic effects of the perioperative stress response may activate micrometastasis as 
well as enhancing the vulnerability to recurrence. COX, cyclooxygenase; VEGF, vascular endothelial 
growth factor; MMPs, matrix metalloproteinases; CTC, circulating tumour cell; NK, natural killer cell.  
 
Figure 2 | Putative mechanisms for post-operative cancer recurrence and metastasis  
A| Following tumour resection, a fraction of cancer cells remain due to incomplete resection margins, 
exfoliation into the surgical field, and distribution across major body cavities during tumour handling. 
B| Some of these cells disseminate via haematogenous and lymphatic routes, leading to spikes in 
circulating tumour cells (CTCs) in the days following surgery. Lymphatic trafficking accompanies 
normal clearance of wound debris and is enhanced by raised hydrostatic pressure from wound 
oedema and innervation of lymphangions by the sympathetic nervous system. C| The inflammatory 
response to surgical tissue trauma initiates recruitment of bone marrow-derived immune cells, 
endothelial cells and fibroblast activation, neovascularization, and release of growth factors and 
cytokines. These conditions, occurring with wound hypoxia and the up-regulation of hypoxia inducible 
factor (HIF)-1α, provide an ideal environment for the re-establishment of residual cancer cells. D| The 
surgical stress response induces inflammation, thrombocytosis, hypercoagulation, and impaired 
immunity. Perioperatively, CTCs may form aggregates and complexes with activated platelets to help 
withstand intravascular stresses and evade both circulating and specialized marginated leukocytes. 
Platelets also release transforming growth factor (TGF)-β and stromal-derived factor (SDF)-1 to 
promote CTC chemotaxis and may initiate transition of CTCs to a more invasive, mesenchymal 
phenotype. E| The systemic inflammatory response to surgery aids CTC margination in distant organ 
capillaries through endothelial activation, platelet interactions, micro-thrombus formation, and 
neutrophil extracellular traps (NETs) which form a pre-metastatic niche. Surgical stress and exposure 
to general anaesthesia give rise to post-operative immunosuppression, providing CTCs a privileged 
period for colonization. COX-2, cyclooxygenase-2; PGE2, prostaglandin-E2; TNF-α, tumour necrosis 
factor-α; IL-6, interleukin-6; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; 
VEGF, vascular endothelial growth factor.  
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